I don't see GC doing any RS greater than a ratio of 1:5. To me that equates to a share price of $0.50 or higher, and I certainly feel we can get there with key events that have yet to be announced. While some feel we must uplist to a significantly higher price than the $2 minimum closing price, I don't feel that is justified as there is plenty of buffer built into the $1 price to maintain listing, plus grace periods that allow the price to recover before any delisting action is taken. So a $2.50 range seems reasonable. I also don't support the suggested $4-$5 uplist price to allow margin buying. I don't feel that is a serious concern for the company, as they would want to minimize the impact of decreased leverage to shareholders in reducing the number of shares they own.
In my past communications with GC, he didn't use the word massive. That word has been tossed around here by investors. GC stated we would not do a large RS. I tend to think that implies a lower threshold where they would move forward on uplisting in conjunction with a RS.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links